Updated overall survival (OS) results of randomized phase III trial of erlotiniti (E) versus (v) docetaxel (D) as second- or third-line therapy in patients with advanced non-small cell lung cancer (NSCLC): Docetaxel and Erlotinib Lung Cancer Trial (DELTA)

被引：0
|
作者：
Ibata, Hidenori
Ando, Masahiko
Asami, Kazuhiro
Okano, Yoshio
Fukuda, Masaaki
Nakagawa, Hideyuki
Kozuki, Toshiyuki
Endo, Tateo
Tamura, Atsuhisa
Kamimura, Mitsuhiro
Sakamoto, Kazuhiro
Yoshimi, Michihiro
Soejima, Yoshifumi
Tomizawa, Yoshio
Isa, Shun-ichi
Takada, Minoru
Saka, Hideo
Kubo, Akihito
Kawaguchi, Tomoya
机构：
[1] Natl Hosp Org, Mie Cent Med Ctr, Tsu, Mie, Japan
[2] Nagoya Univ Hosp, Nagoya, Aichi, Japan
[3] Natl Hosp Org, Kinki Chuo Chest Med Ctr, Sakai, Osaka, Japan
[4] Natl Hosp Org, Kochi Hosp, Kochi, Japan
[5] Natl Hosp Org, Nagasaki Med Ctr, Nagasaki, Japan
[6] Natl Hosp Org, Hirosaki Hosp, Hirosaki, Aomori, Japan
[7] Natl Hosp Org, Shikoku Canc Ctr, Dept Thorac Oncol, Matsuyama, Ehime, Japan
[8] Natl Hosp Org, Mito Med Ctr, Mito, Ibaraki, Japan
[9] Natl Hosp Org, Tokyo Hosp, Kiyose, Japan
[10] Natl Hosp Org, Disaster Med Ctr, Tokyo, Japan
[11] Natl Hosp Org, Yokohama Med Ctr, Yokohama, Kanagawa, Japan
[12] Natl Hosp Org, Fukuoka East Med Ctr, Fukuoka, Japan
[13] Natl Hosp Org, Ureshino Med Ctr, Ureshino, Japan
[14] Natl Nishigunma Hosp, Shibukawa, Japan
[15] Kayo Hosp, Wakayama, Japan
[16] Natl Hosp Org, Nagoya Med Ctr, Dept Resp Med, Nagoya, Aichi, Japan
[17] Aichi Med Univ, Sch Med, Nagoya, Aichi, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.e19003
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19003
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)
    Kawaguchi, Tomoya
    Ando, Masahiko
    Asami, Kazuhiro
    Okano, Yoshio
    Fukuda, Masaaki
    Nakagawa, Hideyuki
    Ibata, Hidenori
    Kozuki, Toshiyuki
    Endo, Takeo
    Tamura, Atsuhisa
    Kamimura, Mitsuhiro
    Sakamoto, Kazuhiro
    Yoshimi, Michihiro
    Soejima, Yoshifumi
    Tomizawa, Yoshio
    Isa, Shun-ichi
    Takada, Minoru
    Saka, Hideo
    Kubo, Akihito
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (18) : 1902 - 1908
  • [2] Randomized phase III trial of erlotinib (E) versus docetaxel (D) as second- or third-line therapy in patients with advanced non-small cell lung cancer (NSCLC) who have wild-type or mutant epidermal growth factor receptor (EGFR): Docetaxel and Erlotinib Lung Cancer Trial (DELTA).
    Okano, Yoshio
    Ando, Masahiko
    Asami, Kazuhiro
    Fukuda, Masaaki
    Nakagawa, Hideyuki
    Ibata, Hidenori
    Kozuki, Toshiyuki
    Endo, Tateo
    Tamura, Atsuhisa
    Kamimura, Mitsuhiro
    Sakamoto, Kazuhiro
    Yoshimi, Michihiro
    Soejima, Yoshifumi
    Tomizawa, Yoshio
    Isa, Shunichi
    Takada, Minoru
    Saka, Hideo
    Kubo, Akihito
    Kawaguchi, Tomoya
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer
    Horgan, A. M.
    Bradbury, P. A.
    Amir, E.
    Ng, R.
    Douillard, J. Y.
    Kim, E. S.
    Shepherd, F. A.
    Leighl, N. B.
    [J]. ANNALS OF ONCOLOGY, 2011, 22 (08) : 1805 - 1811
  • [4] Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer in the Era of Personalized Medicine
    Biswas, Bivas
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (05) : 524 - 524
  • [5] Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer in the Era of Personalized Medicine Reply
    Kawaguchi, Tomoya
    Ando, Masahiko
    Kubo, Akihito
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (05) : 526 - U205
  • [6] Docetaxel versus docetaxel plus irinotecan as second line chemotherapy in advanced non-small cell lung cancer (NSCLC): A randomized phase II trial.
    Pectasides, D
    Farmakis, D
    Pectasides, M
    Kostopoulou, V
    Nikolaou, M
    Koumpou, M
    Gaglia, A
    Kountourakis, P
    Mylonakis, N
    Economopoulos, T
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 625S - 625S
  • [7] Third-line chemotherapy with gemcitabine or docetaxel in patients with advanced non-small cell lung cancer (NSCLC).
    Morgensztern, D
    Lim, WT
    Subramanian, J
    Viswanathan, A
    Govindan, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 694S - 694S
  • [8] COST-EFFECTIVENESS ANALYSIS OF ERLOTINIB VERSUS DOCETAXEL AS A SECOND- OR THIRD-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN KOREA
    Kim, Y. G.
    Lee, E. K.
    [J]. VALUE IN HEALTH, 2010, 13 (07) : A514 - A514
  • [9] Activity and safety of erlotinib as second- and third-line treatment in elderly patients with advanced non-small cell lung cancer: a phase II trial
    David Rossi
    Donatella Dennetta
    Marcello Ugolini
    Vincenzo Catalano
    Paolo Alessandroni
    Paolo Giordani
    Anna Maria Baldelli
    Virginia Casadei
    Francesco Graziano
    S. Luzi Fedeli
    [J]. Targeted Oncology, 2010, 5 : 231 - 235
  • [10] Activity and safety of erlotinib as second- and third-line treatment in elderly patients with advanced non-small cell lung cancer: a phase II trial
    Rossi, David
    Dennetta, Donatella
    Ugolini, Marcello
    Catalano, Vincenzo
    Alessandroni, Paolo
    Giordani, Paolo
    Baldelli, Anna Maria
    Casadei, Virginia
    Graziano, Francesco
    Fedeli, S. Luzi
    [J]. TARGETED ONCOLOGY, 2010, 5 (04) : 231 - 235
12345